Navigation Links
Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
Date:11/11/2011

DURHAM, N.C., Nov. 11, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the American Society of Nephrology's (ASN) Kidney Week 2011 Annual Meeting being held November 8-13, 2011 in Philadelphia, PA.  

V. Ram Peddi, MD, Transplant Nephrologist and Director of Kidney Transplant Research at California Pacific Medical Center, will present data from Chimerix's Phase 1/2 trial evaluating CMX001 in transplant patients with BK virus (BKV) infection.  The poster presentation, entitled "CMX001 Was Well-Tolerated and Without Nephrotoxicity in Renal Transplant and Hematopoietic Stem Cell Transplant Recipients with BK Virus Infection in a Prospective, Randomized, Double-Blind Study," is part of the "Late-Breaking Clinical Trials Poster" session and begins at 10:00 am on Saturday, November 12 at the Philadelphia Convention Center.

"In the Phase 1/2 trial, CMX001 was generally safe and well tolerated when administered to renal transplant (RT) and hematopoietic stem cell transplant (HSCT) recipients," stated Wendy Painter, MD, MPH, Chief Medical Officer of Chimerix, Inc.  "Importantly, no signs of nephrotoxicity were seen following five weekly oral doses of 40 mg and the pharmacokinetics of CMX001 and cidofovir were similar between kidney transplant and bone marrow transplant recipients."  These findings are consistent with results from other CMX001 clinical trials and based on Chimerix's experience with subjects treated under emergency INDs.

CMX001 is being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, pre-emption and treatment of double-stranded DNA (dsDNA) viruses, including herpesviruses and adenoviruses, and as a potential biodefense countermeasure in the event of a smallpox release.  Data from an ongoing, placebo-controlled Phase 2 clinical trial
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chimerix to Present at Stifel Nicolaus 2011 Healthcare Conference
2. Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
3. Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract
4. Chimerix to Present at Two Upcoming Investor Conferences
5. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
6. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
7. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
8. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
9. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
10. Chimerix to Present at Upcoming Investor Conferences
11. Chimerix Initiates Phase 1 Study of CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... InferMed , s ... will augment ... s olutions suite   Elsevier , ... and services, announced today the acquisition of  InferMed , a ... company. InferMed,s Arezzo technology supports clinicians in choosing ...
(Date:7/1/2015)... 2015  UCB, a multinational biopharmaceutical company, and ... in designing, transforming, and running intelligent business operations, ... of their close collaboration in driving transformation that ... services (GBS) finance organization. The Aecus ... work together effectively to embrace the innovative promise ...
(Date:6/30/2015)... June 30, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") ... shares of Resverlogix have approved the resolutions relating ... Limited of 5,600,000 units at a price of ... unit being comprised of one common share and ... of approximately CAD$15 million; and (ii) the amendment ...
(Date:6/30/2015)... 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ), ... that address unmet medical needs in women,s health, ... will present at the Cantor Fitzgerald Inaugural Healthcare ... , 4:45 PM EDTLocation: , Le Parker Meridien ... www.juniperpharma.com, under  ,Investor, or  click here ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... Troy, N.Y. A new research discovery at Rensselaer ... frames for aircraft, watercraft, and automobiles. , Epoxy composites ... jets, planes, and other vehicles. Composite material frames are ... vehicle and boosts fuel efficiency. The downside is that ...
... NATURAL FUELS INDUSTRIES, INC. (Pink Sheets: VGPR) today announced ... the Company to "Fully Compliant", its highest tier for ... over-the-counter into easily identifiable tiers that inform investors whether ... a timely manner. Subsequent to NFI,s recent filing, ...
... ACF Manufacturing Drives Aggressive Conversion ProgramST. LOUIS, March 26 ... materials and services for upstream and downstream processes in ... a member of the Sigma-Aldrich Group (Nasdaq: ... of its dry powder cell culture media continuous milling ...
Cached Biology Technology:Fitter frames: Nanotubes boost structural integrity of composites 2Pink OTC Markets Moves Natural Fuels Industries to Top Tier 2SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free 2SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free 3SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free 4
(Date:6/25/2015)... SALT LAKE CITY , June 25, 2015 /PRNewswire/ ... the first steps toward a healthier, happier life. That,s ... app is designed to do. The cutting-edge, portable health ... and offers real-life solutions to help improve your lifestyle ... Sellers Association awards dinner and gala Wednesday night, USANA,s ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. ... human interface solutions, today announced that Sharp has ... provide secure authentication for its latest flagship smartphone ... more than 200 million shipments of its fingerprint ... reinforces Synaptics, strength, scalability and leadership in the ...
(Date:6/23/2015)... 22, 2015 Research ... of the "Body-Worn Temperature Sensors Market - ... Forecast 2014 - 2020" report to their ... of the global body-worn temperature sensors market. The ... on the basis of types, care setting, patient ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... 19, 2012 Research!America Chair John Edward Porter says federal ... fiscal environment. "The rancorous budget debates between ... nation,s leadership in science and innovation is tenuous at best ... proposals in the House and Senate would put funding for ...
... The boundary between electronics and biology is blurring with ... Oak Ridge National Laboratory of ferroelectric properties in an ... team led by Andrei Kholkin of the University of ... to identify and explain the presence of ferroelectricity, a ...
... Barcelona, Spain, Thursday 19 April 2012: New data presented ... the interferon-free (IFN) revolution in HCV treatment. The much ... that combinations of antivirals offer the hope of shorter, ... following new studies cover the treatment of HCV patients ...
Cached Biology News:ORNL microscopy yields first proof of ferroelectricity in simplest amino acid 2New data suggests interferon-free therapy around the corner for HCV patients 2New data suggests interferon-free therapy around the corner for HCV patients 3